One of the remits of the review was to assess the evidence for prevention and treatment of cardiovascular disease (CVD) with hormone replacement therapy (HRT) [2.4.2]. Rather confusingly, it is then stated in the review under 'Clinical issues that will not be covered' 1 [2.5.2] that this includes 'treatment and/or prevention of chronic diseases that are common in postmenopausal women, such as osteoporosis and CVD' 1 [2.5.2]. It is not clear as to whether or not this latter statement just relates only to non-hormonal treatment.
Introduction [11.2.1]
The introduction to the section highlights the increased risk of CVD following the menopause, regardless of chronological age, inferring (but not stating) that loss of ovarian function itself is an independent risk factor for CVD. Observational studies had shown an association between HRT use and reduction in CVD incidence, but randomised clinical trials (RCTs) suggested an increased risk with HRT initiation at a later age. The aim of this review was thus to determine the CVD risk/benefit for HRT in postmenopausal women.
Review question [11.2.2]
The NICE guideline development group assessed the published literature addressing the effects of HRT on the risk of developing CVD, focussing on women initiating therapy below age 65 years. It also assessed the risk in relation to age, user categories (ever, past and current users), duration of use, timing of initiation following menopause onset, and the effect of the different types and routes of administration of HRT.
Description of included studies [11.2.3]
Five RCTs that 'assessed the effect of HRT in comparison with placebo' 1 [11. 1.3] or no treatment were included in the review, three of which looked at coronary heart disease (CHD) and two looked at blood pressure change. A Cochrane review 2 was not included as it was published after the date of the last update search. It was also stated that it would not have been eligible for inclusion as it did not use age-related restrictions. However, data were presented for women within 10 years of menopause which would have been confined to women under age 65 years. Furthermore, the largest meta-analysis of RCTs on HRT and CHD which included over 39,000 postmenopausal women presented data for women initiating therapy below age 60 years 3 but was also not included in the review. Eighteen comparative cohort studies which compared HRT with no treatment were included. Sample sizes of the included cohort studies varied widely, ranging from 454 to 698,098 cases.
Evidence statements [11.2.5]
The evidence from RCTs in women initiating HRT below age 60 years was in the direction of a reduction in CHD risk with combined HRT or estrogen alone, but most of these findings were non-significant. Significant reductions in CHD outcomes were, however, seen in the Danish study 4 and in the follow-up of the Women's Health Initiative (WHI) estrogen-alone study. 5 As stated above, large meta-analyses of RCTs have shown significant reduction with HRT in such women. With regard to stroke, there was no difference in stroke seen between HRT and placebo or no treatment in women initiating HRT below age 60 years. The quality of evidence from all these studies was regarded as low to very low by the development group.
The evidence from comparative cohort studies showed variable outcomes of either no difference or a reduction in CHD in the individual studies. However, meta-analyses of four cohort studies showed significant reductions with HRT in both CHD outcomes and CVD death. One long-term large prospective cohort study found some evidence of reduced CHD risk with current HRT use for up to 24 years' follow-up. Published subsequent to the review and hence not included, a large population study of 91,130 women from Finland showed a clear significant reduction in CHD death in those under age 60 years with a non-significant reduction in those aged above 60 years. 6 With regard to stroke, there was a significant increase of total stroke with HRT compared to non-users, although one study found evidence of a reduced risk with transdermal HRT. One long-term large prospective cohort study found an increased risk of stroke in those initiating estrogen-alone HRT below age 60 years, but not with combined estrogen-progestogen HRT.
Consideration of clinical benefits and harms [11.2.7.2]
The evidence summarised in the guideline both from RCTs and observational data was for oral HRT compared to non-users initiating therapy below age 65 years. Randomised evidence from several thousand women showed consistently that there was no difference in risk of stroke or myocardial infarction, and these findings were largely supported by observational findings. However, it was noted that observational studies showed significantly reduced CHD risk with HRT use 'compared with no treatment across different follow-up periods (4,10,16 and 20 years) and different HRT durations (1,2,5 or 10 years)' 1 [11.2.7.2]. The group suggested that menopause does not cause CVD, although this is at variance with their introductory comments, and with a wealth of metabolic data 7 and observational outcome data 8 that strongly suggest that menopause may make a considerable contribution to CVD. The group also considered evidence that there is no clear harm in terms of CHD or stroke when HRT is terminated. However, since the review, an observational study of 332,202 women has shown that, in women who had initiated HRT aged under 60 years, during the first year following HRT cessation, there was a significant increase in death from both CHD and stroke. 9
Recommendations [1.3] [11.2.8]
The guideline states the following recommendations:
. 'HRT does not increase cardiovascular risk when started in women aged below 60 years'. 1 They suggest using Tables 1 and 2 1 to explain risks to women. Unfortunately, they do not give reference as to where these numbers came from, they simply give the reference as Appendix M. This has a complete list of references but does not indicate which was used for the tables. I am concerned that these tables are misleading. If, as I suspect, the figures come from the WHI, then most of the changes are not statistically significant. Thus, saying there were '5 more' cases of CHD with HRT may be misinterpreted as meaning these extra cases were due to the HRT, whereas these extra cases have probably arisen by chance rather than due to the intervention.
Other considerations [11.2.7.5]
The group recognised that they could not take into account the potential different effects of HRT on CVD according to dose and type of hormones. A possible lower risk of stroke with transdermal HRT was noted, but again it cannot be clear whether this is primarily an effect of route of administration or dose. 'They highlighted the need for all women around the age of menopause to have their personal cardiovascular risk reviewed on an ongoing basis'. 1 [11.2.7.5] Key conclusions [11. 2.7.6] The group concluded that, for women initiating treatment with estrogen alone or estrogen plus progestogen, there is no convincing evidence that HRT increases the risk of CVD. However, they presumably mean CHD rather than CVD, as they then state that 'there is evidence to show that HRT increases the risk of stroke' 1 [11.2.7.6] after menopause, although this is at variance with their statement in [11.2.7.2].
Comment
The group have rightly emphasised the cardiovascular safety of HRT, with potential benefits in terms of CHD. Any increase in stroke risk is minor in absolute terms because of the very low background incidence in this age group. This should reassure medical practitioners who are considering the prescribing of HRT, as safety is of course paramount. However, it was within the remit of the group to look at prevention of CHD with HRT, and I believe the totality of current data permits the recommendation, or at the very least the consideration, for HRT as an active therapy for the primary prevention of CHD in the early postmenopause. Dose in particular may be crucial to determining the benefit or risk of HRT on CVD, 7 but there is at present insufficient evidence in clinical outcomes to assess this. With the presentation of new findings, some of which have become available subsequent to this report, the group will doubtless want the opportunity to revise their recommendations.
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